MABWELL-B

The company is an innovative biopharmaceutical enterprise with end-to-end, full-industry-chain integration. Adhering to the vision of "turning innovation from a dream into reality" and upholding the mission of "exploring life to benefit health," it leverages breakthrough, first-in-class innovation to deliver biologic innovators that offer superior efficacy and greater accessibility, thereby addressing unmet clinical needs worldwide. The company's core business encompasses the research and development, manufacturing, and commercialization of innovative medicines and biosimilars. Its principal product portfolio includes antibodies, antibody–drug conjugates, recombinant proteins, small-molecule chemical drugs, and other therapeutic agents. The company has been recognized with numerous awards, including the Shanghai Industrial Talent Development Initiative's "Outstanding Case Award," the Institute of Chartered Accountants in Australia's "Recognized Employer" designation, the Starlight List's "2021 China Biologics Innovation Drug Most Promising Growth Award," as well as top honors on the China Pharmaceutical Talent Brand Ranking and the Most Competitive Brand list.